Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis
- PMID: 26794711
- DOI: 10.1016/j.jcyt.2015.11.010
Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis
Abstract
Background aims: Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment option for patients with hematological malignancies. Co-transplantation of multipotent mesenchymal stromal cells (MSCs) during allogeneic HSCT has been explored to enhance engraftment and decrease the risk of graft-versus-host disease (GVHD). We aimed to identify, evaluate and summarize the findings of all relevant controlled clinical studies to determine the potential benefits of MSC infusion during allogeneic HSCT, with regard to the outcomes engraftment, GVHD, post-transplant relapse and survival.
Methods: We conducted a systematic search of electronic databases for relevant controlled clinical studies. Studies included patients of all ages with hematological malignancies receiving allogeneic HSCT with or without infusion of MSCs within a 24-h time frame of transplantation.
Results: Nine studies met our inclusion criteria, including three randomized, one non-randomized and five historically controlled trials, representing a total of 309 patients. Our meta-analyses did not reveal any statistically significant differences in donor engraftment or GVHD. A review of data regarding relapse and overall survival may result in a positive attitude toward intervention with MSCs, but due to heterogeneous reporting, it is difficult to draw any strict conclusions. None of the studies had overall serious risks of bias, but the quality of the evidence is low.
Conclusions: Meta-analysis did not reveal any statistically significant effects of MSC co-transplantation, but the results must be interpreted with caution because of the weak study design and small study populations. We discuss further needs to explore the potential effects of MSCs in a HSCT setting.
Keywords: Allogeneic hematopoietic stem cell transplantation; Engraftment; Evidence-based practice; Graft-versus-host disease; Multipotent mesenchymal stromal cells; Systematic review.
Copyright © 2015 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.Cochrane Database Syst Rev. 2012 Sep 12;(9):CD009159. doi: 10.1002/14651858.CD009159.pub2. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2023 Jun 21;6:CD009159. doi: 10.1002/14651858.CD009159.pub3. PMID: 22972135 Updated.
-
Hematopoietic stem cell translation for relapse of psoriasis. Systematic review.Arch Dermatol Res. 2025 Apr 25;317(1):740. doi: 10.1007/s00403-025-04191-1. Arch Dermatol Res. 2025. PMID: 40278948
-
Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.Cochrane Database Syst Rev. 2023 Jun 21;6(6):CD009159. doi: 10.1002/14651858.CD009159.pub3. Cochrane Database Syst Rev. 2023. PMID: 37341189 Free PMC article.
-
Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support.Cochrane Database Syst Rev. 2017 Jan 27;1(1):CD011305. doi: 10.1002/14651858.CD011305.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2024 May 23;5:CD011305. doi: 10.1002/14651858.CD011305.pub3. PMID: 28128441 Free PMC article. Updated.
-
G-CSF-Primed Peripheral Blood Stem Cell Haploidentical Transplantation Could Achieve Satisfactory Clinical Outcomes for Severe Aplastic Anemia Patients.Transplant Cell Ther. 2025 Jul;31(7):454.e1-454.e11. doi: 10.1016/j.jtct.2025.04.008. Epub 2025 Apr 19. Transplant Cell Ther. 2025. PMID: 40258519
Cited by
-
Hematopoietic Stem Cells in Regenerative Medicine: Astray or on the Path?Transfus Med Hemother. 2016 Jul;43(4):247-254. doi: 10.1159/000447748. Epub 2016 Jul 26. Transfus Med Hemother. 2016. PMID: 27721700 Free PMC article. Review.
-
Graft-Versus-Host Disease Mouse Models: A Clinical-Translational Perspective.Methods Mol Biol. 2025;2907:1-56. doi: 10.1007/978-1-0716-4430-0_1. Methods Mol Biol. 2025. PMID: 40100591 Review.
-
The Effect of Mesenchymal Stem Cell-Derived Extracellular Vesicles on Hematopoietic Stem Cells Fate.Adv Pharm Bull. 2017 Dec;7(4):531-546. doi: 10.15171/apb.2017.065. Epub 2017 Dec 31. Adv Pharm Bull. 2017. PMID: 29399543 Free PMC article. Review.
-
Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.Cochrane Database Syst Rev. 2019 Jan 30;1(1):CD009768. doi: 10.1002/14651858.CD009768.pub2. Cochrane Database Syst Rev. 2019. PMID: 30697701 Free PMC article.
-
Programmed cell death in stem cell-based therapy: Mechanisms and clinical applications.World J Stem Cells. 2021 May 26;13(5):386-415. doi: 10.4252/wjsc.v13.i5.386. World J Stem Cells. 2021. PMID: 34136072 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous